NCT06189170View on ClinicalTrials.gov

Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Safety IssuesTolerance
Interventions
DRUG

KP405

Experimental drug

DRUG

Placebo

Placebo

Trial Locations (1)

Unknown

RECRUITING

MAC, Manchester

Sponsors
All Listed Sponsors
lead

Kariya Pharmaceuticals

INDUSTRY